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Background/Aims
A selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist, ramosetron, inhibits stress-induced abnormal defecation in 
animals and is currently used as a therapeutic drug for irritable bowel syndrome with diarrhea. The aim of this study is to 
investigate the effect of ramosetron on altered gastrointestinal (GI) transit.
Methods
Male guinea pigs weighing approximately 300 g were used. The effect of ramosetron was investigated on altered GI transit 
induced by thyrotropin-releasing hormone (TRH), 5-HT, or mustard oil (MO). GI transit was evaluated by the migration of char-
coal mixture from the pylorus to the most distal point, and expressed as a percentage (%) of charcoal migration (cm) of the 
total length of total small intestine (cm). 
Results
The average charcoal transit was 51.3 ± 20.1% in the control (vehicle) group, whereas in the ramosetron group charcoal 
moved 56.6 ± 21.9%, 46.9 ± 9.14% and 8.4 ± 5.6% of the total small intestine at the concentrations of 10, 30 and 100 
μg/kg, respectively. GI transit after administration of TRH (100 μg/kg), 5-HT (10 mg/kg) or MO (10 mg/kg) was accelerated 
compared to vehicle (5-HT, 94.9 ± 9.22%; TRH, 73.4 ± 14.7%; MO, 81.0 ± 13.7%). Ramosetron inhibited GI transit altered 
by 5-HT, TRH or MO. 
Conclusions
Ramosetron modulated GI transit. We suggest that ramosetron may be therapeutically useful for those with accelerated upper 
GI transit.
(J Neurogastroenterol Motil 2013;19:36-41)
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Introduction
As a potent and selective 5-hydroxytryptamine type 3 receptor 
antagonist (5-HT3RA), ramosetron hydrochloride (ramose-
tron), has been introduced in Japan to treat gastrointestinal (GI) 
symptoms such as nausea and vomiting caused by antineoplastic 
agents.1 5-HT3RAs (e.g., ondansetron and granisetron) have been 
reported to inhibit GI motility and reduce visceral sensitivity.2,3 
Ramosetron also has a long-acting inhibitory effect on stress-in-
duced abnormal defecation in rats, though the drug does not in-
fluence normal defecation.4 Unlike existing antidiarrheal and 
spasmolytic agents, 5-HT3RAs work through inhibition of co-
lonic hyperalgesia.5 Therefore, ramosetron is currently used as a 
therapeutic drug for irritable bowel syndrome with diarrhea 
(IBS-D).6,7 However, few studies have evaluated the effect of ra-
mosetron on upper GI transit.
This study investigated the effects of ramosetron on GI 
transit with 5-HT, thyrotropin-releasing hormone (TRH) and 
mustard oil (MO). The latter two were selected as TRH enhan-
ces serotonin-induced GI motility,8,9 and as MO activates tran-
sient receptor potential ankyrin-1 (TRPA-1) to induce 5-HT re-
lease from enterochromaffin (EC) cells in vitro.10 Furthermore, 
our study verified the inhibitory effects of ramosetron on altered 
GI transit induced by 5-HT, TRH and MO in guinea pigs. 
Materials and Methods
Animals
Adult male Hartley guinea pigs (250-350 g, Orient Bio, Inc., 
Seoul, Korea) were acclimated to their holding room (temper-
ature controlled at 21 ± 1oC, 50 ± 10% humidity and 12-hour 
light/dark cycle). A standard guinea pig diet (7006; Teklad 
Guinea Pig Diet, Harlan Laboratories, Madison, WI, USA) 
and drinking water were provided ad libitum. Guinea pigs were 
deprived of food overnight before the experiment but were al-
lowed free access to water. All experiments were conducted in ac-
cordance with the Guide for the Care and Use of Laboratory 
Animals provided by the Animal Laboratory Ethics Committees 
of the Department of Laboratory Animal Medicine, Medical 
Research Center, Yonsei University College of Medicine.
Drugs and Chemicals
The following drugs and chemicals were used: pentobarbital 
sodium (Hanlim Pharmaceuticals, Seoul, Korea), charcoal 
(Sigma, St. Louis, MO, USA), ramosetron hydrochloride 
(Astellas Pharma, Inc., Tokyo, Japan), 5-HT (Sigma), TRH 
(Sigma) and MO (Sigma). Ramosetron, 5-HT and MO were 
administrated orally with a charcoal mixture. For experiments in-
volving TRH, this drug was mixed in saline and injected sub-
cutaneously (SC) at total dose of 2 mg/kg prior to charcoal mix-
ture administration.
Experimental Design
Assessment of gastrointestinal transit
After being fasted for 24 hours with free access to water, 
guinea pigs were anesthetized by intraperitoneal (i.p.) injection of 
pentobarbital sodium (40 mg/kg). GI transit was measured by 
using the charcoal transit assay. The charcoal mixture consisted 
of charcoal, barium and normal saline mixed in a 1:2:6 ratio. The 
guinea pigs received an intragastric administration of charcoal 
mixture combined with ramosetron, 5-HT and MO through or-
ogastric cannula. TRH was injected SC. After 2 hours, the guin-
ea pigs were sacrificed. The abdomens were opened and the intes-
tines were removed from the pyloric junction to the ileocecal 
valve. GI transit was evaluated as the migration of charcoal mix-
ture from the pylorus to the most distal point of migration and ex-
pressed as a percentage (%) of charcoal migration (cm) through 
the total length of small intestine (cm). The distance moved 
through the small intestine represents both gastric transit and 
small bowel transit. Additionally, small intestine transit is used 
interchangeably with upper GI transit.11 
Effect of ramosetron, 5-hydroxytryptamine, thyrotropin- 
releasing hormone or mustard oil on gastrointestinal 
transit
Ramosetron (10, 30 and 100 μg/kg) was administered via 
charcoal mixture through an orogastric cannula. Likewise, 5-HT 
(1, 5 and 10 mg/kg) and MO (0.1, 1 and 10 mg/kg) were also 
administered by the same method. TRH (1, 10 and 100 μg/kg) 
was administered SC. Unlike the 5-HT and MO group, which 
were given the drug per os, TRH group had its agent subcuta-
neously injected. To offset the effect due to the difference of ad-
ministration, 2 control group was formed. Doses were selected 
based upon the results of preliminary experiments as well as on 
previously published data.12-15
Effect of ramosetron on altered gastrointestinal transit 
induced by 5-hydroxytrytamine, thyrotropin-releasing 
hormone or mustard oil
Ramosetron (10, 30 and 100 μg/kg) was administered via 
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Figure 1. The effect of ramosetron on gastrointestinal (GI) transit. 
Ramosetron inhibits GI transit. *P ＜ 0.01 compared with the control 
group (n = 7).
Figure 2. The effect of ramosetron on altered gastrointestinal (GI) 
transit induced by 5-hydroxytryptamine (5-HT). The 5-HT accele-
rated GI charcoal transit dose-dependently. The maximum effect was 
observed at a dose of 10 mg/kg (*P < 0.01 compared with the control 
group [n = 7]). Ramosetron significantly inhibited the accelerated GI
transit caused by 5-HT (**P < 0.01 compared with the 5-HT group [n
= 6]).
charcoal mixture combined with 5-HT (10 mg/kg) or MO (10 
mg/kg) through an orogastric cannula. TRH (100 μg/kg) was 
concurrently administered via charcoal mixture combined with 
ramosetron (10, 30 and 100 μg/kg) through an orogastric cannula. 
Statistical Methods
Different doses of the same treatment protocol were given at 
the same time-point to determine that the effects of drug treat-
ment on charcoal transit were dose-dependent. The ‘within 
group’ multiple comparisons were assessed by one-way analysis of 
variance. The mean and standard deviation of the mean of char-
coal transit rate for each treatment group were calculated. The 
student’s t test was used to compare individual treatment groups. 
A P-value of less than 0.05 (P ＜ 0.05) was considered to be stat-
istically significant. All data were analyzed using the SPSS ver-
sion 17.0 for Windows software (SPSS Inc., Chicago, IL, USA).
Results
Effect of Ramosetron on Gastrointestinal Transit
The average charcoal transit was 51.3 ± 20.1% in the control 
(vehicle) group (n = 7) (Fig. 1). After oral administration of ra-
mosetron, the transit was 56.6 ± 21.9% (n = 6), 46.9 ± 9.1% (n 
= 6) and 8.4 ± 5.6% (n = 6), at ramosetron doses of 10, 30 and 
100 μg/kg, respectively (P ＜ 0.01). 
Effect of 5-hydroxytryptamine, Thyrotropin-re-
leasing Hormone or Mustard Oil on Gastro-
intestinal Transit 
Oral administration of 5-HT at doses of 1, 5 and 10 mg/kg 
accelerated GI transit of charcoal in a dose-dependent fashion 
(Fig. 2). In the control group (n = 7) the charcoal moved 51.3 ± 
20.1%, whereas the transit for the 5-HT group was 55.1 ± 
20.5% (n = 6), 64.7 ± 20.9% (n = 6) and 94.9 ± 9.2% (n = 6) 
at doses of 1, 5 and 10 mg/kg, respectively. A significant change 
was observed at a 5-HT dose of 10 mg/kg (P ＜ 0.01).
 Similarly, subcutaneous administration of TRH accelerated 
charcoal transit (Fig. 3). The charcoal moved 56.1 ± 18.4% in the 
control group (n = 6), whereas for the TRH group the charcoal 
transit was 45.5 ± 16.9% (n = 6), 52.1 ± 17.4% (n = 6) and 
73.5 ± 14.7% (n = 6) at doses of 1, 10 and 100 μg/kg, 
respectively. The maximum effect was achieved for TRH at a 
dose of 100 μg/kg (P = 0.102). 
Oral administration of MO also accelerated GI transit (Fig. 4). 
In the control group (n = 7) the charcoal moved 51.3 ± 20.1%, 
and in the MO group the charcoal transit was 33.9 ± 15.3% (n = 
6), 61.3 ± 9.8% (n = 6) and 81.0 ± 13.7% (n = 6) at doses of 0.1 
(n = 6), 1 and 10 mg/kg, respectively. A significant difference was 
observed for MO at a dose of 10 mg/kg (P ＜ 0.01).
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Figure 4. The effect of ramosetron on altered gastrointestinal (GI) 
transit induced by mustard oil (MO). MO accelerated GI charcoal 
transit. The maximum effect was observed in MO at a dose of 10 mg/kg
(*P ＜ 0.01 compared with the control group [n = 7]). Ramosetron 
significantly inhibited the accelerated GI transit caused by MO (**P ＜
0.01 compared with the MO group [n = 7]).
Figure 3. The effect of ramosetron on altered gastrointestinal (GI) transit
induced by thyrotropin-releasing hormone (TRH). TRH accelerated GI 
charcoal transit. The maximum effect was observed in TRH at a dose of 
100 μg/kg (*P = 0.102 compared with the control group [n = 6]). 
Ramosetron significantly inhibited the accelerated GI transit caused by 
TRH (**P ＜ 0.05 compared with the TRH group [n = 6]).
Effect of Ramosetron on Altered Gastrointe-
stinal Transit Induced by 5-hydroxytryptamine, 
Thyrotropin-releasing Hormone or Mustard Oil
Oral administration of ramosetron at doses of 10 and 30 μg/kg 
inhibited 5-HT, TRH and MO-induced accelerated GI transit (Fig. 
2-4). In particular, ramosetron at a dose of 30 μg/kg significantly in-
hibited the accelerated GI transit caused by 5-HT at a dose of 10 
mg/kg (P ＜ 0.01, n = 6), TRH at a dose of 100 μg/kg (P ＜ 0.01, n 
= 6) and MO at a dose of 10 mg/kg (P ＜ 0.01, n = 7).
Discussion
Ramosetron, a selective 5-HT3RA, inhibits GI transit. This 
effect was well demonstrated by its inhibitory effects on accel-
erated GI transit caused by 5-HT, TRH and MO in this study.
The 5-HT is an important signaling molecule that involves 
peristaltic, secretory, vagal and nociceptive reflexes.16 This sig-
naling molecule is found in the GI tract in the interneurons that 
terminate in the myenteric and submucosal plexuses,17 is released 
from EC cells by vagus nerve stimulation, and induces a release 
of acetylcholine from excitatory (cholinergic) neurons.18 TRH 
stimulates the centers of the brain which control the vagal-enteric 
nervous systems, and involves cholinergic and serotonergic 
mechanisms.19 The smooth muscle contraction that is elicited is 
influenced by changes of neurotransmitter release, either pos-
itively or negatively.17 TRH also induces release of serotonin, 
which results in accelerated GI transit and causes diarrhea.13,20 
Similarly, MO induces 5-HT release from EC cells in vitro by 
way of TRPA-1, which is highly expressed in both the intestine 
and the stomach.10 TRPA-1 agonists are reported to have a con-
tractile effect in isolated mouse intestine in vivo, but the effect of 
TRPA-1 agonists on GI motility in guinea pigs has not been 
verified.21 In a previous experiment in rabbits, the contractile re-
sponses of allyl isothiocyanate, which is a TRPA-1 agonist, were 
reduced by ramosetron.22
The 5-HT3 receptors (the original 5-HT M receptor) are 
distributed widely in both the GI tract and the central nerve sys-
tem, and result in increased intestinal secretion and alteration of 
peristaltic activity.16,23 In animals, 5-HT3RAs have been found to 
inhibit stress-induced abnormal defecation in animals.9,12 
Furthermore, 5-HT3RAs already have a therapeutic use for 
IBS-D, and their effectiveness is well-known. 5-HT3RAs have 
also been confirmed to have an inhibitory effect on lower GI 
transit,5,12 but their effects and mechanism on the upper GI tract 
(stomach and small intestine) have not been verified. 
Previously, Doihara et al24 showed that intragastric admin-
istration of 1 mg/kg allyl isothiocyanate facilitated phasic con-
tractions in the gastric antrum and jejunum, and that these effects 
were inhibited by pretreatment with ruthenium red, a TRPA-1 
antagonist. However, in another study involving guinea pigs, the 
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selective 5-HT3RA ondansetron increased the rate of gastric 
emptying in vivo,25 although the precise mechanisms have not 
been elucidated.
Ramosetron is a potent and selective 5-HT3RA. Ohta et al
26 
have suggested that ramosetron may achieve long-lasting binding 
to 5-HT3 receptors because ramosetron possesses the distinctive 
ability to maintain an active 3-dimensional chemical conforma-
tion. This drug has already proven to be effective for IBS-D in 
both animal and clinical studies. Recently, although Hirata et al27 
showed that ramosetron significantly inhibited the delayed gastric 
emptying in a corticotrophin releasing factor and soybean oil-in-
duced rat model, few studies have investigated the effects of ra-
mosetron on altered upper GI transit. Therefore, we hypothe-
sized that ramosetron may affect the motor function of the small 
bowel as well as the stomach, which was investigated by using 
charcoal GI transit. Aquiring the data on net effect of the gastric 
and small intestinal charcoal transit makes our study different 
from previous studies.
Our study demonstrated that ramosetron inhibits normal GI 
transit and that it also inhibits the accelerated GI transit induced 
by 5-HT, TRH and MO in guinea pigs. Along these lines, pre-
vious animal and preliminary human studies have indicated that 
5-HT3RAs may facilitate activity dependent on the degree of 
basal tone.17,23 A few studies have also shown that 5-HT3RAs ac-
celerated delayed gastric emptying in animal models.28 On the 
other hand, Talley et al29 reported that ondansetron, a selective 
5-HT3RA, did not significantly alter small intestine transit and 
oral to cecal transit time in healthy volunteers. Troisetron, a se-
lective 5-HT3RA, has been found to either modestly increase 
gastric emptying or reduce it in healthy volunteers.30 The action 
of 5-HT3RAs to modify contraction-relaxation responses would 
be dependent on the relative balance of excitatory-inhibitory 
tone.17,23 Therefore, 5-HT3RAs might reduce motor activity in 
the presence of an abnormally increased basal activity. The transit 
time at lower doses of TRH and MO is actually slower compared 
to the control group in this study. Different doses of TRH and 
MO do affect GI transit. It was shown in higher doses that they 
accelerated GI transit. Perhaps this is due to a balance of in-
hibitory and excitatory tone at the neuromuscular junction. It will 
necessitate further investigation and more studies to explain the 
odd phenomena that lower doses of TRH and MO causes appa-
rent inhibitory effect on GI transit. 
In conclusion, this stuty showed that 5-HT, TRH and MO 
accelerated GI transit. Ramosetron, which is a 5-HT3RA, in-
hibited 5-HT, TRH and MO-induced accelerated GI transit. 
Therefore, we suggest that ramosetron may be therapeutically 
useful for accelerated upper and lower GI transit.
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